Ascendis Pharma A/S Announces Initiation of a Phase 1 Single Ascending Dose Study of TransCon Treprostinil
TransCon Treprostinil has been designed as an inert prodrug that enables a sustained release of unmodified treprostinil in circulation following a once-daily self-administered subcutaneous injection. TransCon Treprostinil is intended to produce a pharmacokinetic profile comparable to continuously infused prostacyclins, with the benefit of a more convenient route of administration, while avoiding the infusion site pain and risk of bloodstream infections associated with currently marketed infused prostacyclin therapies.
"The initiation of this Phase 1 study for our second wholly-owned clinical program is an important milestone for Ascendis," stated Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma. "Our clinical stage pipeline is now comprised of long-acting TransCon prodrugs that incorporate both small molecules and proteins, demonstrating the broader potential of the TransCon technology platform."
The Phase 1 study is a single ascending dose study that will evaluate pharmacokinetic, injection tolerability, and safety parameters in a healthy volunteer population. Ascendis expects to report results from this study in mid-2015.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.